Brief: Redcare Pharmacy FY Adjusted EBITDA Up At EUR 53.5 Mln

Redcare Pharmacy NV

05/03/2024 05:36

March 5 (Reuters) - REDCARE PHARMACY NV  RDC.DE :
    * SUCCESSFUL COMPLETION OF A RECORD YEAR FOR REDCARE
PHARMACY:
GROWTH 49%, ADJUSTED. EBITDA MARGIN UP 3.7PP TO 3%; GUIDANCE
ACHIEVED IN ALL ITS ELEMENTS.
    * FY GUIDANCE FOR 2024: CONTINUATION OF BOTH FAST SALES
GROWTH
(30-40%) AND SOLIDLY POSITIVE MARGINS (ADJUSTED. EBITDA 2-4%)
EXPECTED
    * FY TOTAL GROUP SALES EUR 1.8 BN, UP 49% VERSUS. PRIOR YEAR
    * OUTLOOK 2024: TOTAL SALES TO INCREASE TO EUR 2.3-2.5
BILLION, A
GROWTH OF 30% TO 40%.
    * OUTLOOK 2024: NON-RX SALES GROWTH 15-25%.
    * OUTLOOK 2024: MEDISERVICE EXPECTED TO GROW BY MID-SINGLE
DIGITS.
    * OUTLOOK 2024: TOTAL REDCARE ADJUSTED EBITDA MARGIN 2% TO
4%.
    * MID- TO LONGER-TERM GUIDANCE CONTINUES TO BE AN ADJUSTED
EBITDA
MARGIN IN EXCESS OF 8%
    * ADJUSTED. EBITDA MARGIN 3% FOR FULL YEAR 2023, +3.7PP
VERSUS.
2022, WITH MAJOR IMPROVEMENTS IN BOTH DACH AND INTERNATIONAL
SEGMENTS
    * FY GROUP'S ADJUSTED EBITDA INCREASED TO A POSITIVE EUR
53.5
MILLION FROM EUR -8 MILLION PRIOR YEAR

Source text for Eikon:  ID:nEQbqKmDta 
Further company coverage:  RDC.DE 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))